

# Zanubrutinib with obinutuzumab for treating relapsed or refractory B- cell follicular lymphoma after 2 or more treatments (terminated appraisal)

Technology appraisal guidance

Published: 29 May 2024

[www.nice.org.uk/guidance/ta978](https://www.nice.org.uk/guidance/ta978)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable to make a recommendation about the use in the NHS of zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma in adults after 2 or more treatments. This is because BeiGene has requested a delay to the evidence submission.

## Information

If NHS organisations wish to consider zanubrutinib for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6150-4